ArticleAnnals of surgical oncology2022
Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location.
Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Investigation of the regional lymph nodes in left-sided pancreas tumors by intraoperative identification using indocyanine green fluorescence imaging.Surgery today · 2026Article
- Article
- Preoperative prediction of metastatic body-tail peripancreatic lymph nodes as a guide for surgical decision-making in pancreatic neck ductal adenocarcinoma.Updates in surgery · 2026Article
- Article
- Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer.Surgical endoscopy · 2025Article
- Laparoscopic and Open Distal Pancreatectomy-An Initial Single-Institution Experience with a Propensity Score Matching Analysis.Life (Basel, Switzerland) · 2025Article
- Prognostic significance of lymph node metastasis in pancreatic tail cancer: A multicenter retrospective study.Annals of gastroenterological surgery · 2024Article
- Review
- Surgical management of pancreatic ductal adenocarcinoma: a narrative review.Translational gastroenterology and hepatology · 2023Review
- Minimally invasive radical antegrade modular pancreatosplenectomy: routine vs. modified.Journal of minimally invasive surgery · 2022Review
- Importance of an appropriate number of examined lymph nodes in patients with pancreatic cancer-the more the better?Hepatobiliary surgery and nutrition · 2022Article
- ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-Peripancreatic Lymph Nodes for all Left-Sided Pancreatic Cancer Patients?Annals of surgical oncology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal lymph node (LN) dissection for left-sided pancreatic cancer based on tumor location has remained unknown. In particular, the efficacy of LN dissection around the common hepatic artery and the celiac axis for distal tumors has not been established. This study was designed to elucidate the frequency and prognostic impact of LN metastasis, focusing on tumor location.
methodsData from 110 patients with invasive pancreatic cancer who underwent distal pancreatectomy between 2007 and 2020 were collected. We used a quantitative value-the distance between the left side of the portal vein and the right side of tumor (DPT)-to define the tumor location. LN stations were divided into two groups: peripancreatic lymph nodes (PLN) and non-PLN. We then analyzed the frequency of LN metastasis based on the tumor location and prognostic factors.
resultsNon-PLN metastasis was observed in 7.3% of patients. Non-PLN metastasis was found only in patients with a DPT < 20 mm. Patients with non-PLN metastasis exhibited a significantly worse prognosis than those with only-PLN metastasis (median survival time: 20.3 vs. 42.5 months, p = 0.048). Multivariate analysis for survival indicated that tumor size > 4 cm (hazard ratio [HR]: 2.23, p = 0.012) and metastasis in the non-PLN region (HR: 3.02, p = 0.015), and inability to undergo adjuvant chemotherapy (HR: 2.81, p = 0.0018) were also associated with poor prognosis.
conclusionsDissection of the non-PLN region can be avoided in selected patients with DPT ≥ 20 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.